中文摘要：

HLA-A2.1-associated 肽，从人的黑瘤房间提取了，被用来由 epitope 宪法，活跃的肽顺序描述和合成的肽确认为黑瘤特定的 HLA-A2.1-restricted 细胞毒素的 T 淋巴细胞(CTL ) 学习 epitopes。CTL 从包含肿瘤的节点被产生由在 vitro 刺激，开始与自体同源的黑瘤房间并且随后与 allogeneic HLA-A2.1 积极黑瘤房间。CTL 能自体同源的细胞溶解和 allogeneic HLA-A2.1 积极黑瘤，然而并非 HLA-A2.1 否定黑瘤或 HLA-A2.1 积极非黑瘤。黑瘤的细胞溶解能被 anti-CD3， anti-HLA 一级和 anti-HLA-A2.1 禁止单音的同种细胞的抗体。HLA-A2.1 分子被颠倒的阶段高效液体层析被免疫亲密关系列层析和进一步的 fractionated 从净化溶解的人的黑瘤房间净化。部分为他们重新组成的能力被估计有 HLA-A2.1 积极处理抗原的变异的 T2 房间的黑瘤特定的 epitopes。三座体质山峰被观察在喂奶脱氢酶版本试金。集体 spectrometry 和离子交换高效液体层析分析被用来识别肽 epitopes。有 948 的 mass-to-charge 比率的肽通常由九氨基酸残余组成。从体质实验的数据证实合成的肽包含了 epitopes 并且与 HLA-A2.1 联系并且由黑瘤特定的 CTL 认出了的肽在这些不同黑瘤房间是在场的。这些肽能潜在地为 CTL 在免疫疗法在新奇的基于肽的反肿瘤疫苗被利用。

英文摘要：

HLA-A2.1-associated peptides, extracted from human melanoma cells, were used to study epitopes for melanoma-specific HLA-A2.1-restricted cytotoxic T lymphocytes （CTLs） by epitope reconstitution, active peptide sequence characterization and synthetic peptide verification. CTL were generated from tumor-involved nodes by in vitro stimulation, initially with autologous melanoma cells and subsequently with allogeneic HLA-A2.1 positive melanoma cells. The CTLs could lyse autologous and aUogeneic HLA-A2. 1 positive melanomas, but not HLA-A2.1 negative melanomas or HLA-A2.1 positive non-melanomas. The lysis of melanomas could be inhibited by anti-CD3, anti-HLA class I and anti-HLA-A2.1 monoclonal antibodies. HLA-A2.1 molecules were purified from detergent-solubilized human melanoma cells by immunoaffinity column chromatography and further fractionated by reversed phase high performance liquid chromatography. The fractions were assessed for their ability to reconstitute melanoma-specific epitopes with HLA-A2.1 positive antigen-processing mutant T2 cells. Three reconstitution peaks were observed in lactate dehydrogenase release assay. Mass spectrometry and ion-exchange high performance liquid chromatography analysis were used to identify peptide epitopes. Peptides with a mass-to-charge ratio of 948 usually consist of nine amino acid residues. The data from reconstitution experiments confirmed that the synthetic peptides contained epitopes and that the peptides associated with HLA-A2.1 and recognized by melanoma-specific CTL were present in these different melanoma cells. These peptides could be potentially exploited in novel peptide-based antitumor vaccines in immunotherapy for CTL.